References
  1. A. Gadducci, S. Carinelli, G. Aletti, Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists, Gynecol. Oncol. 144 (3) (2017) 637–646.
  2. Viswanathan AN, Deavers MT, Jhingran A et al. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004; 93: 27–33.
  3. Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol 2007; 34: 57–63.
  4. Chung HH, Jang MJ, Jung KW et al. Cervical cancer incidence and survival in Korea: 1993–2002. Int J Gynecol Cancer 2006; 16: 1833–1838.
  5. Kim YM, Jung MH, Kim DY, et al. Small cell carcinoma of the uterine cervix: clinicopathologic study of 20 cases in a single center. Eur J Gynaecol Oncol. 2009;30:539Y542.
  6. Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111:1394Y1402.
  7. S. Kuji, Y. Hirashima, H. Nakayama, S. Nishio, T. Otsuki, Y. Nagamitsu, et al., Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan, Gynecol. Oncol. 129 (3) (2013) 522–527.
  8. Zivanovic O, Leitao MM Jr., Park KJ, et al. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009;112:590Y593.
  9. Wang KL, Chang TC, Jung SM, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer. 2012;48:1484Y1494.
  10. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20:4665Y72.
  11. Liao LM, Zhang X, Ren YF, et al. Chromogranin A (CgA) as poor prognostic factor in patients with small cell carcinoma of the cervix: results of a retrospective study of 293 patients. PloS One. 2012;7:e33674.
  12. Kuji S, Hirashima Y, Nakayama H, et al. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan. Gynecol Oncol. 2013;129:522Y527.
  13. Naidoo J, Teo MY, Deady S, et al. Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation? J Thorac Oncol. 2013;8:1215Y1221.
  14. Satoh T, Takei Y, Treilleux I, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix[J]. International Journal of Gynecological Cancer Official Journal of the International Gynecological Cancer Society, 2014, 24(9):S102.
  15. J.M. Lee, K.B. Lee, J.H. Nam, et al. Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Annals of Oncology 19: 321–326, 2008.
  16. N. Bhatla, D. Aoki, D.N. Sharma, e Zivanovic t al., Cancer of the cervix uteri, Int. J. Gynecol. Obstet. 143 (2018) 22–36.
  17. Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol 1991;4:586–93.
  18. Stoler MH, Mills SE, Gersell DJ, Walker AN. Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer. Am J Surg Pathol 1991;15:28–32.
  19. Ginger J. Gardner, Diane Reidy-Lagunes, Paola A. Gehrig. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecologic Oncology 122 (2011) 190–198.
  20. J.G. Cohen, D.S. Kapp, J.Y. Shin, R. Urban, A.E. Sherman, L.M. Chen, et al., Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients, Am. J. Obstet. Gynecol. 203 (4) (2010) 347 e1–6.
  21. NCCN clinical practice guidelines in Oncology:Small Cell Lung Cancer. Version 1, 2021. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 2 October 2020. In.
  22. Loehrer PJ Sr, Einhorn LH, Greco FA. Cisplatin plus etoposide in small cell lung cancer. Semin Oncol. 1988 Jun;15(3 Suppl 3):2-8.
  23. Roth, B. J., Johnson, D. H., Einhorn, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive smallcell lung cancer: A phase III trial of the Southeastern Cancer Study Group. Journal of Clinical Oncology 10(2), 282–291.
  24. Noda, K., Nishiwaki, Y., Kawahara, M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. The New England Journal of Medicine 346(2), 85–91.
  25. C-H Kuo, C-C Hsieh, M-L Chan, et al. Small cell carcinoma of the esophagus: a report of 16 cases from a single institution and literature review. Ann Thorac Surg. 2011;91(2):373-8.
  26. J E Lee, S H Hong, H I Jung, et al. Small-cell neuroendocrine carcinoma of the ileum: case report and literature review. BMC Surg. 2019;19(1):135.
  27. N Shahab. Extrapulmonary small cell carcinoma of the bladder. Semin Oncol. 2007;34(1):15-21.
  28. X Pei, L B Xiang, S Ye, et al. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology. 147;589-596.
  29. Bermudez A, Vighi S, Garcia A, Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol Oncol 2001;82:32–9.
  30. Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998;83:712–8.
  31. Chang TC, Hsueh S, Lai CH, Tseng CJ, Lee KF, Huang KG, et al. Phase II trial of neoadjuvant chemotherapy in early-stage small cell cervical cancer. Anticancer Drugs 1999;10:641–6.
Table 1. General characteristics.